Articles
| Open Access |
DOI: Therapy using medicinal plants to cure stomach ulcer illness and research on the characteristics of these plants
Ibragim Askarov , Andijan State University, Andijan, Uzbekistan Khabibullo Kodirov , Andijan Medical Institute, Andijan, UzbekistanAbstract
The World Health Organization states that 10.0–15.0% of people worldwide suffer from peptic ulcers of the stomach and duodenum. The structure of gastrointestinal tract illnesses includes both benign and malignant neoplasms, peptic ulcer diseases, acute and chronic gastritis, gastroduodenitis, and functional dyspepsia. Furthermore, these plants' leaves and their The autoxidation activity of combinations with different quantities was shown to be stronger when assessed using the method of suppression of the adrenaline autoxidation process.
When the AA% indications of the mixture of leaves and stems were analyzed, the plantago and hypericum linariifolium blend in a 1:1 ratio showed the highest antioxidant activity. Consequently, a 1:1 by weight ratio was proposed for the application of this plantago and hypericum linariifolium combo as a potential medicinal food component.
Keywords
World Health Organization, Therapy, Medicinal Plants
References
Асқаров И.Р. Табобат қомуси. Т.: "Мумтоз сўз". –2019. –Б. 1142.
Асқаров И.Р. Фитотерапия. Дарслик. Тошкент. "Фан ва техналогиялар нашриёт-матбаа уйи". 2023 й
Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40(6):775–781. doi: 10.1136/gut.40.6.775.
Nguyen N.H., Fumery M., Dulai P.S. et al. Comparative efficacy and tolerability of pharmaco- logical agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018;3(11):742–753. doi: 10.1016/ S2468-1253(18)30231-0.
Pokrotnieks J., Sitkin S. A proposed treatment algorithm for mild to moderate ulcerative colitis–with an emphasis on budesonide foam and mucosal healing. J Gastroenterol. 2018;53(6):799–800. doi: 10.1007/s00535-018-1458-y.
Rutgeerts P., Sandborn W.J., Feagan B.G. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi: 10.1056/NEJMoa050516.
Reinisch W., Sandborn W.J., Rutgeerts P. et al. Long-term infliximab maintenance therapy for ul- cerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201–211. doi: 10.1002/ibd.21697.
Sands B.E., Moss A.C., Armuzzi A. et al. DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID main- tenance therapy: results from OwCTAVE open. J Crohns Colitis. 2018;12(1 Suppl.):S049. doi: 10.1093/ ecco-jcc/jjx180.063.
Yarur A.J., Rubin D.T. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Pa- tients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015;21(7):1709–1718. doi: 10.1097/ MIB.0000000000000380.
Zhang Y., Chen D., Wang F. et al. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif. 2019;52(2):e12559. doi: 10.1111/cpr.12559.
Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PDR. Patient reported symptoms during an ulcerative colitis flare: a qualitative focus group study. Eur J Gastroenterol Hepatol. 2009;21(5):558- 564. doi:10.1097/MEG.0b013e328326cacb
Wolfe BJ, Sirois FM. Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease. Qual Life Res. 2008;17(6):877-886. http://www.embase.com/search/res
Watanabe K, Gardiner S, Arai S. Notable gaps between patients’ and physicians’ perspectives on communication and disease man agement in Japan: multifaceted ad hoc analyses of the global ulcerative colitis narrative survey for further optimal care. Therap Adv Gastroenterol. 2022;15:17562848221095372. doi:10.1177/17562848221095372
Article Statistics
Copyright License
Copyright (c) 2025 Ibragim Askarov, Khabibullo Kodirov
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.